Susan L. Davis Pharm.D.

Susan L. Davis Pharm.D.

Title

Interim Associate Dean for Pharmacy,
Clinical Professor of Pharmacy Practice

Department

Pharmacy Practice

Office Location

EACPHS, Dean's Suite Office 2629

Phone

313-916-8724

Email

sldavis@wayne.edu

Susan L. Davis Pharm.D.

Degrees and Certifications

  • 2005 - Fellowship in Infectious Diseases Outcomes Research, Wayne State University
  • 2003 - Pharmacy Practice Residency, Detroit Receiving Hospital
  • 2002 - Doctor of Pharmacy, University of Michigan

Positions and Employment

  • July 2021-Present - Interim Associate Dean for Pharmacy, Wayne State University
  • 2018-Present - Clinical Professor, Wayne State University
  • 2005-Present - Infectious Diseases Pharmacy Specialist, Henry Ford Hospital
  • 2011-2018 - Clinical Associate Professor, Wayne State University
  • 2005-2011 - Clinical Assistant Professor, Wayne State University

Awards and Honors

  • 2021 - Wayne State University Board of Governors Faculty Recognition Award
  • 2015 - WSU EACHPHS Research Excellence Award
  • 2012 - Society of Infectious Diseases Pharmacists, Outstanding Clinical Practice Award
  • 2012 - Wayne State University Doctor of Pharmacy Program, Preceptor of the Year
  • 2008 - ASHP Foundation, Pharmacy Residency Excellent Awards - New Preceptor of the Year, 2008
  • 2007 - SMSHP Committee Service Award
  • 2006 - Roche Preceptor of the Year (selected by graduating PharmD class)
  • 2006 - Henry Ford Hospital LAPP Preceptor of the Year

Professional Memberships

  • 2012-Present - Making a Difference In Infectious Diseases Pharmacotherapy
  • 2003-Present - Society of Infectious Diseases Pharmacists
  • 2003-Present - American Society for Microbiology
  • 2001-Present - American College of Clinical Pharmacy
  • 1998-Present - American Society of Health-Systems Pharmacists
  • 2003-2014 - Infectious Diseases Society of America
  • 2002-2011 - Southeast Michigan Society of Health-System Pharmacists
  • 2002-2010 - Michigan Pharmacist’s Association

Areas of Expertise

  • Antimicrobial stewardship practice, education and research
  • Epidemiology of healthcare associated infections
  • Clinical and economic consequences of antimicrobial resistance

Primary Research Interest

  • Epidemiology of bacterial infections
  • Clinical and economic implications of antimicrobial resistance
  • Optimizing patient outcomes and antimicrobial exposure

Recent Publications

  • COVID-19 Treatment Guidelines Panel. Coronavirus Diseases 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available athttps://www.covid19treatmentguidelines.nih.gov/.
  • Wagner JL, Rhodes NJ, Scheetz MH, Bosso JA, Goff DA, Rybak MJ,Davis SL; MAD-ID Research Network. Opportunities for antimicrobial stewardship amongcarbapenem-treated patients in 18 North American hospitals. Int J Antimicrob Agents. 2020 Apr 10:105970. doi: 10.1016/j.ijantimicag.2020.105970.
  • Heil EL, Aitken SL, Nix DE, Drew R, Rose WE, Davis SL,Justo JA, Fish DN, Pogue JM; Society of Infectious Diseases Pharmacists. Recommended Revisions to the National SEP-1 Sepsis Quality Measure: A commentary by the Society of Infectious Diseases Pharmacists on the Infectious Diseases Society of America Position Paper. Pharmacotherapy. 2020 Apr;40(4):368-371. doi: 10.1002/phar.2384.
  • Mercuro NJ, Gill CM, Kenney RM, Alangaden GJ, Davis SL. Treatment and outcomes of Enterococcus faecium bloodstream infections in solid organ transplant recipients. Transpl Infect Dis. 2020 Apr;22(2):e13251. doi: 10.1111/tid.13251. Epub 2020 Feb 11.
  • Jorgensen SCJ, Trinh TD, Zasowski EJ, Lagnf AM, Simon SP, Bhatia S, Melvin SM, Steed ME, Finch NA, Morrisette T, Estrada SJ, Rosenberg JR, Davis SL,Rybak MJ. Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections. Antimicrob Agents Chemother. 2020 Mar 24;64(4). pii: e02291-19. doi: 10.1128/AAC.02291-19.
  • Jorgensen SCJ, Murray KP, Lagnf AM, Melvin S, Bhatia S, Shamim MD, Smith JR, Brade KD, Simon SP, Nagel J, Williams KS, Ortwine JK, Veve MP, Truong J, Huang DB, Davis SL, Rybak MJ. A Multicenter Evaluation of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections. Infect Dis Ther. 2020 Mar;9(1):89-106. doi: 10.1007/s40121-019-00278-1.
  • Jorgensen SCJ, Trinh TD, Zasowski EJ, Lagnf AM, Bhatia S, Melvin SM, Simon SP, Rosenberg JR, Steed ME, Estrada SJ, Morrisette T, Davis SL, Rybak MJ. Evaluation of the INCREMENT-CPE, Pitt Bacteremia, and qPitt scores in patients with carbapenem-resistant Enterobacteriaceae infections treated with ceftazidime-avibactam. Infect Dis Ther 2020 Feb doi: 10.1007/s40121-020-00288-4.
  • Alosaimy S, Jorgensen SCJ, Lagnf AM, Melvin S, Carlson TJ, Garey KW, Allen D, Venugopalan V, Veve M, Athans V, Saw S, Yost CN, Davis SL, Rybak MJ. Real-world multicenter analysis of clinical outcomes and safety of meropenem-vaborbactam in patients treated for serious gram-negative bacterial infections. Open Forum Infect Dis. 2020; 7(3):ofaa051 doi: 10.1093/ofid/ofaa051
  • Gill CM, Kenney RM, Makowski C, Davis SL. High dose daptomycin is well tolerated via 2-minute infusion. Hospital Pharmacy. 2020 January. https://doi.org/10.1177/0018578719897076
  • Jorgensen SCJ, Trinh TD, Zasowski EJ, Lagnf AM, Bhatia S, Melvin SM, Steed ME, Simon SP, Estrada SJ, Morrisette T, Claeys KC, Rosenberg JR, Davis SL, Rybak MJ. Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections.Open Forum Infect Dis. 2019 Dec 6;6(12):ofz522. doi: 10.1093/ofid/ofz522.
  • Bianchini ML, Kenney RM, Lentz RL, Zervos MJ, Malhotra M, Davis SL.Discharge delays and costs associated with outpatient parenteral antibiotic therapy for high-priced antibiotics. Clin Infect Dis 2019. Online Oct 2019. DOI:10.1093/cid/ciz1076
  • Pogue JM, Kaye KS, Veve MP, Patel TS, Gerlach AT, Davis SL, Puzniak LA, File TM, Olson S, Dhar S, Bonomo RA, Perez F. Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2019 Sep 23. pii: ciz816. doi: 10.1093/cid/ciz816.
  • Veve MP, Stuart M, Davis SL. Comparison of neutropenia between ceftaroline and ceftriaxone in patients receiving at least 7-days of β-lactam therapy for severe infections. Pharmacotherapy. 2019 Jun 30. doi: 10.1002/phar.2301.
  • Gill C, Kenney RM, Hencken L, Mlynarek ME, Alangaden G, Samuel LP, Davis, SL. T2 Candida versus Beta-D-Glucan to Facilitate Antifungal Discontinuation in the Intensive Care Unit. Diagnostic Microbiology and Infectious Diseases. 2019, May https://doi.org/10.1016/j.diagmicrobio.2019.04.016.
  • Rhodes NJ, Wagner JL,Davis SL, Bosso JA, Goff DA, Rybak MJ, Scheetz MH; MAD-ID Research Network. Trends in and predictors of carbapenem consumption across North American hospitals: results from a multicenter survey by the MAD-ID Research Network. Antimicrob Agents Chemother. 2019 Jun 24;63(7).
  • Veve MP, January SE, Kenney RM, Zoratti EM, Zervos MJ, Davis SL.Impact of a reported beta lactam allergy on management of methicillin sensitive Staphylococcus aureus bloodstream infections. J Pharm Pract. 2019 April. doi: 10.1177/0897190019841737.
  • Claeys KC, Zasowski EJ, Davis SL,Rybak MJ. Open-Label Randomized Trial of EarlyClinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant Staphylococcus aureus. Infect Dis Ther. 2019 Jun;8(2):199-208. doi: 10.1007/s40121-019-0242-5. Epub 2019 Mar 27.
  • Jorgensen SCJ, Lagnf AM, Bhatia S, Singh NB, Shammout LK,Davis SL,Rybak MJ. Diagnostic Stewardship: A Clinical Decision Rule for Blood Cultures in Community-Onset Methicillin-Resistant Staphylococcus aureus (MRSA) Skin and Soft Tissue Infections. Infect Dis Ther. 2019 Jun;8(2):229-242. doi: 10.1007/s40121-019-0238-1. Epub 2019 Feb 19.
  • Bianchini M, Mercuro NJ, Kenney RM, Peters M, Samuel LP, Swiderek J, Davis SL.Pharmacists improve care of critically-ill patients with community-acquired pneumonia. Am J Health-System Pharm 76(12), 861-868.
  • Liu J., Kaye K.S., Mercuro N.J., Davis S.L., Patel T.S., Petty L.A., Pais G.M., Scheetz M.HIt is time to define antimicrobial never events. Infect Control Hosp Epidemiol 2019; 40(2): 206
  • Claeys KC, Zasowski E.J., Lagnf A.M., SabaghaN., Levine D.P., Davis S.L., Rybak M.J. Development of a Risk-Scoring Tool to Determine Appropriate Level of Care in Acute Bacterial Skin and Skin Structure Infections in an Acute Healthcare Setting. Infectious Diseases and Therapy 2019; 7(4); 495
  • Musgrove M.A., Kenney R.M., Kendall R.E., Peters M., Tibbetts R., Samuel L., Davis S.L. Microbiology comment nudge improves pneumonia prescribing. Open Forum Infectious Diseases 5(7): ofy162
  • Rybak MJ, Zasowski EJ, Jorgensen SJ, Lagnf AM, Davis SL,Mendelsohn AB, Margaritis V.Risk Factors for Bloodstream Infections Among an Urban Population with Skin and Soft Tissue Infections: A Retrospective Unmatched Case-Control Study. Infectious Diseases and Therapy 2019; 8(1):75-85
  • Ashley ED, Davis SL, Heil EL, LaplanteKL, Chahine EB, Bosso JA. Best care for patients is achieved through multidisciplinary stewardship. Clin Infect Dis 2018; 67(10): 1637
  • Mercuro NJ, Kenney RM, Abreu-Lanfranco, O, Davis SL. Ambulatory Quinolone Prescribing: Moving from Opportunity to Implementation. Clin Infect Dis, April 2018, doi.org/10.1093/cid/ciy315
  • Mercuro NJ, Kenney RM, Samuel L, Tibbetts RJ, Alangaden GJ, Davis SL. Stewardship opportunities in viral pneumonia: why not the immunocompromised? Transplant Infect Dis. 2018:e12854. doi.org/10.1111/tid.12854
  • Jorgensen SCJ, Mercuro NJ, Davis SL, Rybak MJ. Delafloxacin: place in therapy and review of microbiologic, clinical and pharmacologic properties. Infect Dis Ther 2018 Mar 31. doi: 10.1007/s40121-018-0198-x.
  • Veve MP, Greene JB, Williams AM, Davis SL, Lu N, Shnayder Y, Li DX, Noureldine SI, Richmon JD, Lin LO, Hanasono MM, Pipkorn P, Jackson RS, Hornig JD, LightT, Wax MK, Yiu Y, Bekeny J, Old M, Hernandez D, Patel UA, Ghanem TA. Multicenter Assessment of Antibiotic Prophylaxis Spectrum on Surgical Infections in Head and Neck Cancer Microvascular Reconstruction. Otolaryngol Head Neck Surg. 2018 Mar 1:194599818756299. doi: 10.1177/0194599818756299.
  • Davis SL and Wagner JL. Quasi-Experimental Research Design. Chapter In: ACCP Updates in Therapeutics: Infectious Diseases Pharmacy Preparatory Review Course Workbook. American College of Clinical Pharmacy, Kansas, 2018.
  • Wagner JL, Davis SL. Principles of IV to PO Switch. Chapter in: Antibiotic Stewardship Principles and Practice. 1stEdition, 2017. Laplante Ket al Eds. CABI Publishing, Oxfordshire, England.
  • Athans V, Veve MP, Davis SL. Trowels and Tribulations: Review of Antimicrobial-Impregnated Bone Cements in Prosthetic Joint Surgery. Pharmacotherapy. 2017; 37(12):1565-1577.
  • Claeys KC, Zasowski EJ, Trinh TD, Lagnf AM, Davis SL, Rybak MJ. Antimicrobial stewardship opportunities in critically ill patients with gram negative lower respiratory tract infections: a multicenter cross-sectional analysis. Infect Dis Ther. 2018 Mar;7(1):135-146. doi: 10.1007/s40121-017-0179-5
  • Veve MP, Davis SL, Williams AM, McKinnon JE, Ghanem TA. Considerations for antibiotic prophylaxis in head and neck cancer surgery. Oral Oncology. 2017;74:181-187.
  • Suleyman, G, Grunwald J, Kenney RM, Davis SL, Zervos MJ, Weinmann A. Impact of antimicrobial stewardship consultation service at an academic institution. Infect Dis Clin Pract. 2017;25(5);268-71.
  • Wilson NM, Kenney RM, Alangaden G, Tibbetts RJ, Samuel LP, Davis SL. T2 Magnetic Resonance Assay Improves Timely Management of Candidemia. Journal of Antimicrobial Stewardship (JAMS) 2017; 1(1): 12-18.
  • Trinh TD, Zasowski EJ, Claeys KC, Lagnf AM, Kidambi S, Davis SL, Rybak MJ. Multidrug-resistant Pseudomonas aeruginosa lower respiratory tract infections in the intensive care unit: Prevalence and risk factors. Diagn Microbiol Infect Dis 2017;89(1):61-66.
  • Claeys KC, Zasowski EJ, Lagnf AM, Levine DP, Davis SL, Rybak MJ. Novel Application of Published Risk Factors for Methicillin-Resistant S. aureus in Acute Bacterial Skin and Skin Structure Infections. Int J Antimicrob Agents. 2017 doi: 10.1016/j.ijantimicag.2017.05.015
  • Flynt LK, Kenney RM, Zervos MJ, Davis SL. The Safety and Economic Impact of Cefazolin versus Nafcillin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections. Infect Dis Ther; 2017.Jun;6(2):225-23 
  • Starosta K, Davis SL, Kenney RM, Peters M, To L, Kalus JS. Creating objective and measurable PGY1 residency graduation requirements. Am J Health-Syst Pharm. 2017; 74 (6) 389-396
  • Carreno JJ, Kenney RM, Divine G, Vazquez JA, Davis SL.Randomized controlled trial of a strategy to prevent nephrotoxoxicity in patients receiving vancomycin (STOP-NT). Ann Pharmacother. 2017; 51(3):185-193
  • Zasowski EJ, Trinh TD, Claeys KC, Casapao AM, Sabagha N, Lagnf AM, Klinker KP, Davis SL,Rybak MJ. Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e02015-16. doi: 10.1128/AAC.02015-16.
  • Claeys KC,Zasowski EJ, Casapao AM, Lagnf AM, Nagel JL, Nguyen CT, Hallesy JA, Compton MT, Kaye KS, Levine DP, Davis SL, Rybak MJ. Daptomycin Improves Outcomes in a Propensity Matched Analysis of Early Daptomycin versus Vancomycin for Methicillin-Resistant S. aureus Bloodstream Infection. Antimicrob Agents Chemother. 2016Sep 23;60(10):5841-8
  • Cook A, Martin C, Rowe AS, Davis SL, Paloucek F. Problems with the current approach to residency research. AJHP 2016; 73(23):1918-20.
  • Athans V, Kenney RM, Wong J, Davis SL. Outpatient use of ceftaroline fosamil versus vancomycin for osteoarticular infection: a matched cohort study. Journal of Antimicrobial Chemotherapy. 2016; 71(12):3568-3574.
  • Wagner JL, Kenney RM, Vazquez JA, Ghanem TA, Davis SL. Surgical prophylaxis with gram-negative activity for reduction of surgical site infections after microvascular reconstruction for head and neck cancer. Head and Neck. 2016;38(10):1449-1454.
  • Rhodes NJ, Wagner JL,Gilbert E, Crew PE, Davis SL, Scheetz MH. Days of therapy and antimicrobial days: similarities and differences between consumption metrics. Infect Control Hosp Epidemiol. 2016;37:971-973
  • Veve MP, Wagner JL, Kenney RM, Grunwald JL, Davis SL. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum beta-lactamase urinary tract infections. Int J Antimicrob Agents 2016; 48(1):56-60
  • Kenney RM, Cole KA, Perry MB, Dumkow LE, Samuel LP, Zervos MJ, Davis SL. Reply to: Urinary Tract Infections: Resistance is futile. Antimicrob Agents Chemother 2016 60(4):2598
  • Zasowski EJ, Claeys KC, Lagnf AM, Davis SL, Rybak MJ. Time is of the essence: the impact of delayed antibiotic therapy on patient outcomes in hospital-onset enterococcal bloodstream infections. Clin Infect Dis 2016;62(10):1242-50.
  • Claeys KC, Lagnf AM, Hallesy JA, Compton MT, Gravelin AL, Davis SL, Rybak MJ. Pneumonia caused by methicillin-resistant Staphylococcus aureus: does vancomycin heteroresistance matter? Antimicrob Agents Chemother 2016; 60(3):1708-16
  • Cole KA,Kenney RM, Perri MB, Dumkow LE, Samuel LP, Zervos MJ, Davis SL.Outcomes of Aminopenicillin Therapy for Vancomycin-Resistant Enterococcal Urinary Tract Infections. Antimicrobial Agents and Chemotherapy. 2015 Dec;59(12):7362-6.
  • Athans V,Santarossa M, Kenney RM, Davis SL. Systematic approach to antimicrobial restriction.Am J Health Syst Pharm. 2015 Aug 1;72(15):1264-5.
  • Carreno JJ, Kenney RM, Bloome M, McDonnell J, Rodriguez J, Weinmann A, Kilgore PE, Davis SL. Evaluation of pharmacy generalists performing antimicrobial stewardship services.Am J Health Syst Pharm. 2015 Aug 1;72(15):1298-303.
  • Claeys KC, Lagnf AM, Patel TB, Jacob MG, Davis SL, Rybak MJ. Acute Bacterial Skin and Skin Structure Infections Treated with Intravenous Antibiotics in the Emergency Department or Observational Unit: Experience at the Detroit Medical Center.Infect Dis Ther. 2015 Jun;4(2):173-86.
  • Wagner JL, Kenney RM, Tibbetts RJ, Davis SL. Secular trends associated with Enterobacteriaceae with a Cefepime-susceptible-dose-dependent MIC. Antimicrob Agents Chemother; 2015:59(3):1822-3